Madrigal Pharmaceuticals, Inc.

MASH-focused biopharma anchored by commercial Rezdiffra and an expanding combination-development strategy.

Back to company catalog

Metabolic / liver disease (MASH) · Oral THR-beta agonist & RNAi combination strategies · Commercial + Phase 3

Compare report options